GlaxoSmithKline, Britain’s biggest drugs maker, has agreed to divest several of its over-the-counter (OTC) European brands to Omega Pharma for €470 million (£391 million).
The brands being divested include Lactacyd, Abtei, Solpadeine, Zantac, Nytol and Beconase, which together generated sales of approximately £185 million in 2011. The divestment is expected to be completed in the second quarter of 2012, subject to regulatory approvals.
GlaxoSmithKline (GSK) said it expected the net cash proceeds from the transaction to be approximately £310 million.